Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.3964) per share and revenue of $1.62 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. On average, analysts expect Relay Therapeutics to post ($1.61) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

Relay Therapeutics Trading Up 2.8%

Relay Therapeutics stock opened at $17.76 on Tuesday. The firm has a market cap of $3.89 billion, a price-to-earnings ratio of -11.35 and a beta of 1.72. The stock has a fifty day simple moving average of $18.47 and a two-hundred day simple moving average of $14.99. Relay Therapeutics has a 12 month low of $5.95 and a 12 month high of $21.27.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the sale, the insider directly owned 21,904,963 shares in the company, valued at $424,956,282.20. The trade was a 21.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sanjiv Patel sold 48,199 shares of the company’s stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $18.10, for a total transaction of $872,401.90. Following the sale, the chief executive officer directly owned 471,301 shares of the company’s stock, valued at $8,530,548.10. The trade was a 9.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 6,149,344 shares of company stock worth $119,185,625. 5.04% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

RLAY has been the topic of a number of research analyst reports. Citizens Jmp upped their price target on Relay Therapeutics from $21.00 to $26.00 and gave the company a “market outperform” rating in a report on Monday, August 10th. HC Wainwright lifted their price objective on Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, October 2nd. JPMorgan Chase & Co. upped their target price on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Finally, Barclays upped their target price on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites.

The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways.